Body Systems

Liver Diseases6 Results found

Studies recruiting participants:

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)

The primary objectives of this study are to evaluate the effect of Obeticholic Acid treatment compared to placebo on 1) histological improvement and 2) liver-related clinical outcomes in patients with non-cirrhotic nonalcoholic steatohepatitis (NASH) with liver fibrosis.

Recruiting
Principal Investigator 
Eric M. Yoshida
Body Locations and Systems 
Liver Diseases
Area 
Vancouver
Age 
18-85

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) (RESOLVE-IT)

The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic steatohepatitis (NASH) and fibrosis.

Recruiting
Principal Investigator 
Eric M. Yoshida
Body Locations and Systems 
Liver Diseases
Area 
Vancouver
Age 
18-75